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Background & aims: This participant-blinded parallel-group randomized placebo-controlled study
demonstrated that alfacalcidol (vitamin D analogue) preserves beta cell function in newly diagnosed type
1 diabetes (T1DM) in children.
Methods: Subjects from outpatient clinic were randomized to intervention and control groups. Inclusion:
(1) age 8e15, (2) T1DM, (3) duration <8 weeks, (4) no chronic diseases, (5) stable diet. Exclusion: (1)
vitamin D, calcium supplements or fortiﬁed foods, (2) hypercalcemia. Intervention group received
alfacalcidol 0.25 mg twice daily, while control group received placebo. Insulin given physician-titrated to
blood glucose. Safety monitored by serum calcium and phosphate. Beta cell function assessed at 0, 3, 6
months using fasting C-peptide (FCP) and daily insulin dosage per body weight (DID). Primary outcome
measured using multivariate repeated measures GLM-ANOVA, with FCP and DID as primary measures
and age, gender, sunlight exposure, 25-hydroxy vitamin D, and HbA1c as covariates.
Results: Of 61 subjects, 7 dropped out. GLM-ANOVA showed that groups were different (p¼ 0.019, Eta-
squared¼ 0.087), with no signiﬁcant covariates. FCP was higher and DID lower in the intervention group,
with males having stronger responses to alfacalcidol (p¼ 0.001). No adverse effects were observed.
Conclusions: The study conﬁrmed that alfacalcidol can safely preserve beta cell function in newly diag-
nosed T1DM in children, with a stronger effect in males.
Clinical Trial Reg. No: IRCT201205159753N1
 2013 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism.
Open access under CC BY-NC-ND license.1. Introduction
Type 1 diabetes in children imposes a signiﬁcant health and
economic burden to both patients and society. A recent studyan leukocyte antigen; VDR,
lecalciferol; HbA1c, glycated
, fasting C-peptide; DID, daily
riate general linear modeling
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for Clinical Nutrition and Metabolsuggests that the lifetime costs of diabetes in type 1 diabetes patients
are disproportionately higher than for type 2 diabetes, and that
elimination of the disease would result in savings of an estimated
$10.6 billion foreachnewcohort annually in theUnited States alone.1
The global variation in the incidence of type 1 diabetes among
children is very large, both between and within ethnic groups, even
in locations in close geographical proximity.2 This suggests that
both genetic and environmental factors play a role in the etiology of
this disease.
In type 1 diabetes 1A subtype, there is autoimmune destruction
of the insulin-producing beta cells in the islets of Langerhans. There
is usually some residual beta cell function in newly diagnosed type
1 diabetes, and this proportion is higher in older children.3 The
genetic component of this condition is very strong and is known to
be linked to the human leukocyte antigen (HLA) complex, while
very little is known about the environmental factors that trigger itsism. Open access under CC BY-NC-ND license.
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discordant for type 1 diabetes, the evidence for non-genetic envi-
ronmental factors inﬂuencing disease susceptibility is strong and
deserves further investigation to unravel potentially effective
interventional strategies.
The vitamin D hormone system has been implicated in the
pathogenesis of several autoimmune diseases, including type 1
diabetes. Vitamin D appears to modulate the immune system, by
regulating tolerance in both cellular and humoral immunity to self-
antigens, protecting pancreatic islets against cytokine-induced
apoptosis via down-regulation of the Fas receptor.5 Vitamin D
deﬁciency contributes to loss of self-tolerance and is associated
with a higher incidence of autoimmune disease, while replacement
leads to improvement of immune-mediated symptoms.6 Polymor-
phism in the vitamin D receptor (VDR) has been shown to predict
onset of type 1 diabetes, while sunlight exposure and consequent
vitamin D production inﬂuences expression of the various VDR
alleles.7,8 In addition to its immunoregulatory functions, vitamin D
may also play a direct role in the control of insulin gene expression
by pancreatic beta cells.9
In sun-rich Iranwhere this studywas conducted, the incidence of
type 1 diabetes in children is relatively low, with a male to female
ratio of 0.7.10 The greater incidence in females is possibly related to
the cultural practice of full body clothing in public, and hence
reduced sunlight exposure compared tomales. It hasbeenpreviously
shown that HLA-DR and -DQ alleles together with VDR gene poly-
morphisms are strongly associated with type 1 diabetes in Iran.11
Another study in nearby Qatar showed that type 1 diabetes occurs
more frequently with low serum vitamin D levels, poor dietary
vitamin D intake, and limited sunlight exposure.12 It has been dem-
onstrated that temperature, latitude, and hence sunlight exposure
account for about 40% of the variance in type 1 diabetes risk.13
Alfacalcidol (1-alpha-hydroxycholecalciferol) is an analogue of
vitamin D that is converted to calcitriol by hepatic metabolism, but
with a much longer duration of action (15e20 days for alfacalcidol,
3e5 days for calcitriol).14 Although both compounds have a similar
risk of hypercalcemia, the prolonged duration of action and
reduced renal load give a favorable risk-beneﬁt proﬁle for alfa-
calcidol compared with calcitriol.15
A previous clinical study using calcitriol and nicotinamide in
early type 1 diabeteswas inconclusive and showedonlya temporary
reduction in insulin dosage, while having a non-signiﬁcant effect on
beta cell function.16 Another study utilizing only calcitriol showed
no signiﬁcant effects on any of the observed parameters, although
there was a temporary slowing of beta cell functional decline mid-
way through the study period.17 However, a third study on adult-
onset latent autoimmune diabetes did demonstrate preservation
of beta cell function using alfacalcidol, while another study showed
that cholecalciferol slowed deterioration of residual beta cell func-
tion.18,19 In spite of the strong laboratory and epidemiological data
linking vitamin D insufﬁciency to type 1 diabetes risk, we can see
that the clinical evidence is somewhat ambivalent.
As alfacalcidol has been used with success in adult-onset latent
autoimmune diabetes, this study is intended to demonstrate that
supplementation with alfacalcidol can preserve islet beta cell
function in newly diagnosed type 1 diabetes in children and ado-
lescents. This was done by comparing fasting C-peptide and insulin
requirement over the study period between the intervention and
control groups.
2. Materials and methods
The study was approved by the Ethics Committee of the Endo-
crinology and Metabolism Research Center, Tehran University of
Medical Sciences (E-00100) in accordance with current guidelineson Good Clinical Practice and the Declaration of Helsinki, with
informed consent obtained from parents of the children.
The study was designed as a single blinded parallel-group ran-
domized controlled clinical trial of efﬁcacy. Subjects were recruited
from the pool of patients referred for newly diagnosed type 1
diabetes to the outpatient diabetes clinic in Shariati Hospital and
the Children Medical Center of the Tehran University of Medical
Sciences.
Inclusion criteriawere: (1) age between 8 and 15 years old at the
time of recruitment, (2) satisﬁed the criteria for diagnosis of type 1
diabetes, (3) duration of clinical disease less than 8 weeks, (4)
without any medical co-morbidities or chronic diseases, and (5)
been on a stable diabetic diet for the previous week. Patients were
excluded if: (1) they had consumed cholecalciferol, calcium, multi-
vitamin, or mineral supplements during the previous 3 months, (2)
consumed vitamin D-fortiﬁed foods on a regular basis, or (3) had
hypercalcemia deﬁned as a serum calcium greater than 2.7 mmol/L
(10.8 mg/dl).
The diagnosis of type 1 diabetes was made based on criteria
from the American Diabetes Association, without the use of HbA1c
(glycated hemoglobin) (pre-2010 criteria) as there is some con-
troversy over its use for diagnosis of type 1 diabetes.20 Differenti-
ation from type 2 diabetes was made solely on clinical grounds as
the utility of tests such as autoantibody markers and measures of
islet beta cell function have not been established.21
Patients who met the criteria and consented for inclusion were
assigned to an intervention and control group using computer-
generated simple randomization with a 1:1 allocation ratio. Ran-
domization and assigning of participants were supervised by the
primary investigator. The control group received standard insulin
treatment plus placebo (Zahravi Pharmaceutical Company, Tabriz,
Iran) while the intervention group received standard insulin
treatment plus alfacalcidol (One-Alfa; LEO Pharma, Ballerup, Den-
mark) in labeled packaging. This was done for a period of six
months, with subjects and laboratory personnel blinded to the
intervention, but not the care providers or investigators performing
the analysis.
In the ﬁrst twoweeks of the study, subjects received one capsule
of alfacalcidol (0.25 mg daily) or placebo with lunch, after which
serum calcium was checked corrected for albumin using Payne’s
formula.22 If serum calcium was within the normal range (8.5e
10.5 mg/dl) for the intervention group, the dose was increased to
one capsule of alfacalcidol each with lunch and dinner, otherwise
only one capsule of alfacalcidol with one placebo capsulewas given.
The dosage for the control group was automatically increased to
two placebo capsules.
Drug toxicity was monitored by measuring serum calcium and
phosphate every two weeks for the ﬁrst month, then monthly for
the remainder of the study period. If hypercalcemia was detected,
alfacalcidol was stopped immediately until serum calcium nor-
malized, and then restarted at half the previous dose. Every two
weeks, patients returned unused capsules to the clinic, and were
given newcapsules for the next twoweeks. Adherence to treatment
was monitored by counting the number of capsules returned.
Sunlight exposure was quantiﬁed using a sunlight exposure ques-
tionnaire modiﬁed from an existing instrument that has been
validated for use in children and adolescents, with a score range
from 4 to 14.23,24
2.1. Standard insulin treatment
Blood samples were drawn at 0, 3, and 6 months to measure the
biochemical indices listed below. The subject’s insulin requirement
was recorded at months 0, 1, 2, 3, and 6, together with body weight.
This was done with the subjects standing, shoes and heavy clothing
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Birmingham, United Kingdom). The dosage was recorded only if it
was stable for three consecutive days. If the dosage was recently
changed, then the next stable dose was recorded instead.
Subjects were trained to self-monitor blood glucose (SMBG),
which was done four times daily (pre-meal and bedtime). These
readings were recorded together with any hypoglycemic symp-
toms, accompanied by a food and physical activity diary. At physi-
cian discretion, SMBG was performed up to eight times daily when
glycemic excursions were frequent. The glucose target range was
set as 80e120 mg/dl before meals and less than 180 mg/dl two
hours after meals. A physician made weekly or biweekly contact
with subjects or their parents by telephone to adjust the insulin
dosage according to SMBG readings. They received short (regular)
and intermediate-acting (NPH) insulin as two to three injections
daily, depending on the glycemic pattern from SMBG. The SMBG
record book together with the food and physical activity diary were
inspected when subjects came for blood testing.
2.2. Measured biochemical indices
Serum calcium, phosphate, albumin, and HbA1c were deter-
mined by spectrophotometry using commercial kits (Pars Azmoon,
Teheran, Iran) with a Hitachi 902 autoanalyzer (Roche Diagnostics
GmbH, Mannheim, Germany). Serum 25-hydroxy vitamin D was
measured using an enzymeimmunoassay (25-hydroxy vitamin D
EIA kit; Immunodiagnostics Systems, Boldon, UK) with a measure-
ment sensitivity of 5 nmol/l, and an intra- and inter-assay coefﬁ-
cient of variation of 5.9% and 5.1%, respectively. Serum C-peptide
was measured after fasting overnight for at least 8 hours by
immunoassay (C-Peptide AccuBind ELISA; Monobind, Lake Forest,
California) with an inter- and intra-assay precision of 7.2% and 6.5%,
respectively.
2.3. Statistical analysis
Baseline characteristics for the treatment groups, along with
subjects who dropped out, were compared using an unpaired T-test
or Chi-square test as appropriate (Table 1). Residual islet beta cell
function was assessed using fasting serum C-peptide (FCP) and
daily insulin dosage (DID) per body weight to maintain euglycemia.
The comparison between the treatment groups over the study
period was quantiﬁed using Multivariate General Linear Modeling
Repeated Measures ANOVA (GLM-ANOVA). Normality was checked
for FCP and DID using the KolmogoroveSmirnov test, and equality
of variances using Levene’s test. The assumptions of equality ofTable 1
Baseline characteristics of study subjects, and HbA1c at 3 and 6 months follow-up.
Variable Intervention
group (n¼ 29)
Control group
(n¼ 25)
P-value
Age (years) 10.2 2.5 11.1 1.6 0.118
Gender
Girls 22 17 0.520
Boys 7 8
Time since diagnosis (days) 44 14 38 18 0.238
Serum 25(OH)D (ng/ml) 13.9 6.0 12.5 6.4 0.432
FCP (ng/ml) 0.40 0.19 0.40 0.21 0.997
Insulin dose (U/kg/day) 0.63 0.19 0.60 0.12 0.621
Sunlight exposure score 10.1 1.9 9.6 1.1 0.271
HbA1c (%) baseline 8.2 1.0 8.2 1.0 0.996
HbA1c (%) 3 months 7.1 0.8 7.5 1.0 0.088
HbA1c (%) 6 months 6.8 0.9 7.1 0.8 0.275
Comparisons between groups used an unpaired T-test for scalar variables or the Chi-
square test for categorical variables. Data are means 1 s.d.covariances and sphericity were tested using Box’s M and Mauch-
ly’sW tests, respectively. Besides FCP and DID as the within-subject
factors, other covariates were age, gender, sunlight exposure score,
25-hydroxy vitamin D, and HbA1c at baseline. Multivariate com-
parisons were done using the PillaieBartlett Trace statistic as this is
more robust to violation of model assumptions.25 The HuynheFeldt
correction was applied when the sphericity assumption was vio-
lated. The GLM-ANOVA was evaluated using a 10% level of
signiﬁcance.
Power analysis was done using G*Power 3.1.3 for repeated
measures ANOVA aiming to detect a partial Eta-squared of 0.059
(medium effect size), signiﬁcance level of 0.05, 95% power, and two
groups, giving a total sample size for both groups of 44 for three
time periods (0, 3, 6 months).26,27 Assuming a 25% dropout rate,
a minimum of 59 subjects was required for the study.
All computations were performed using SPSS for Windows
version 19.0 (SPSS Inc, Chicago, Illinois, USA) and Microsoft Excel
2007 (Microsoft Corp., Redmond, Washington, USA). Statistical
tests were two-tailed and conducted at 5% level of signiﬁcance
unless otherwise stated.
3. Results
A total of 61 subjects were recruited in autumn of 2010
(September to December), of which 7 dropped out for personal
reasons mainly due to the travel distance to the study center. There
was no signiﬁcant difference in age or gender between those who
dropped out and the other subjects (p¼ 0.205 and p¼ 0.415,
respectively). Of the remaining 54 subjects, 29 belonged to the
intervention group and 25 to the control group (Fig. 1). During the
study, 5.1% of dispensed capsules were returned (4.6% alfacalcidol,
5.6% placebo). The mean age of the patients was 10.1 years (s.d. 2.1
years) and the mean duration since diagnosis was 43 days (s.d. 15
days). The treatment groups were similar in age, duration of dis-
ease, and other characteristics at baseline. There was a non-
signiﬁcant trend for HbA1c to be lower in the intervention group
at months 3 and 6 (Table 1). Serum calcium and phosphate
remained within normal limits for all subjects throughout the
study.
All FCP and DID measurements had a normal distribution
(KolmogoroveSmirnov 0.256e0.911). Error variances were equal
for FCP (Levene’s test 0.107e0.548) but not for DID (Levene’s test
0.001e0.129). The assumption of equality of covariances was sat-
isﬁed (Box’sM 0.154). The assumption of sphericity was satisﬁed for
FCP (Mauchly’sW 0.495) but not for DID (Mauchly’sW< 0.001). For
GLM-ANOVA, multivariate comparisons show that the treatment
groups have a different pattern of change in FCP and DID over the
study period (p¼ 0.019 partial Eta-squared¼ 0.087 overall,
p¼ 0.076 partial Eta-squared¼ 0.078 FCP, p¼ 0.056 partial Eta-
squared¼ 0.093 DID). None of the covariates tested showed a sig-
niﬁcant effect in the GLM-ANOVA analysis.
The within-subject contrasts show that the differences between
the treatment groups were most marked between months 3e6 for
FCP (p¼ 0.049) and between months 0e3 for DID (p¼ 0.052). This
was conﬁrmed on the charts of FCP and DID which showed that the
changes in DID preceded that of FCP. In addition, it could be seen
that the gap between the treatment groups for DID began to narrow
towards the end of the study period where the difference became
non-signiﬁcant (p¼ 0.285) (Fig. 2).
The between-subject effects show that for DID, there were sig-
niﬁcant differences between the treatment groups (p¼ 0.008), and
also between genders (p¼ 0.001), with a strong interaction com-
ponent (p¼ 0.011). The interaction component was examined by
looking at the DID chart which shows that males had a stronger
response to alfacalcidol with a lower trough DID than females.
Assessed for eligibility (n= 171)
Excluded (n= 110)
♦ Not meeting inclusion criteria (n= 75)
♦ Declined to participate (n= 35)
Mostly due to travel distance
Analyzed (n= 29)
♦ Excluded from analysis (n= 0)
Allocated to intervention (n= 31)
♦ 4.6% of dispensed alfacalcidol unused
Allocated to control (n= 30)
♦ 5.6% of dispensed placebo unused
Analyzed (n= 25)
♦ Excluded from analysis (n= 0)
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Fig. 1. Recruitment ﬂow diagram according to the 2010 CONSORT statement.34
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the FCP chart shows that males improved their FCP levels at the end
of the study period while females did not. The overlap between the
treatment groups likely obscured the relationship and rendered the
contrasts non-signiﬁcant for FCP (Fig. 3).Error Bars: +
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From the results of this study, it does appear that supplemen-
tation with alfacalcidol preserved islet beta cell function in newly
diagnosed type 1 diabetes in children and adolescents as evidenced/- 1 SE
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The effect was however relatively modest with partial Eta-squared
ranging between 0.078 and 0.093, which was only slightly above
the medium effect size (partial Eta-squared 0.059) that this study
was designed to detect.27
It was interesting to note that changes in DID occurred before
there were any detectable differences in FCP. Logically, endogenous
insulin production (FCP) should fall before the exogenous insulin
requirement (DID) increases. In this case, the likely explanation is
that FCP does not detect early beta cell loss as effectively as post-
prandial C-peptide. When there is a modest reduction of beta cell
reserve, the pancreas is still able tomaintain basal insulin secretion,
which is what FCP measures. The post-prandial insulin peak would
however be blunted, thus requiring exogenous insulin to maintain
euglycemia. A similar pattern has been observed in the evolution of
type 2 diabetes with loss of post-prandial glycemic control pre-
ceding changes in inter-prandial and later fasting glycemia.28
Another interesting observation was that males had a stronger
response to alfacalcidol than females. Baseline sun exposure scores
and 25-hydroxy vitamin D levels were higher in males than females
(p¼ 0.001 and p¼ 0.012, respectively), likely because males tend to
spend more time outdoors during the hot Iranian summer while
females are more modestly clothed, the effects of which were fur-
ther enhanced by the timing of the study in autumn (Fig. 4). When
DID and sun exposure scores were analyzed separately, GLM-
ANOVA analysis showed highly signiﬁcant and large between-
subject effects (p¼ 0.007 partial Eta-squared¼ 0.150), further
highlighting the association between sun exposure and DID.27 One
possible explanation for the differing response between genders is
that sunlight exposure may moderate autoimmunity, thus render-
ing males more responsive to alfacalcidol treatment.29
4.1. Clinical relevance
The results from this study are generalizable to early type 1
diabetes in children older than 8 years worldwide, as the HLA al-
leles associated with type 1 diabetes prevalent in the Iranian pop-
ulation are similar to those in other populations, suggestinga comparable pattern of autoimmunity.11,30 The economic impli-
cations of reducing the incidence of type 1 diabetes are huge, given
that the lifetime costs of type 1 diabetes are much higher than for
type 2 diabetes.1
The use of alfacalcidol instead of calcitriol allows higher dosages
to be used with lower risk of hypercalcemia, and this increases its
potential as a therapeutic agent. The previous studies using calci-
triol were limited by the low dosages used to avoid adverse effects,
A. Ataie-Jafari et al. / Clinical Nutrition 32 (2013) 911e917916and this likely contributed to the small effect sizes even though the
trends were broadly similar to the results from this study.16,17,31
It is interesting to note that one of the studies which demon-
strated preservation of beta cell function utilized cholecalciferol,
which has a long terminal half-life of weeks to months and has
some protection against toxicity due to feedback inhibition of renal
1-alpha hydroxylase.19,32 There is also the possibility that the short
half-life of calcitriol leads to ﬂuctuating serum levels which may
inadequately suppress the autoimmune process.
4.2. Study weaknesses
There are a number of areas in which the study could have been
improved. The use of FCP was less appropriate than post-prandial
C-peptide, which was used in other studies investigating early
type 1 diabetes.33 There was also no data on VDR gene poly-
morphisms which may affect individual responses to alfacalcidol,
althoughmostof theprevious studies similarly lack this information.
The studydesign only allowed detection of amediumeffect size, and
as the actual effectsweremodest, we used a 10% level of signiﬁcance
in the GLM-ANOVA analysis so thatwe could pick up any trends that
were present. Finally, the study period was too short to detect
whether beta cell function could be preserved in the longer term,
although the trends observed in this study suggest that thismay not
be the case as in the earlier studies using calcitriol (Fig. 2).16,17
4.3. Research implications
While the effects in this study were modest, the lack of signif-
icant changes in calcium and phosphate suggest that there is room
to increase the dosage of alfacalcidol in subsequent studies. Im-
provements in methodology such as a larger sample size, a longer
follow-up period, and the use of post-prandial C-peptide would
certainly help to study early changes as well as demonstrate long-
term efﬁcacy. It appears that autoimmunity in type 1 diabetes is
harder to suppress in younger patients, and stratiﬁcation by age
and inclusion of an older post-adolescent cohort would allow this
factor to be properly explored.18,33 Finally, the link between gender,
autoimmunity, and sunlight exposure needs to be examined in
greater detail with autoantibody testing, dendritic cell function,
T-cell phenotype, as well as stratiﬁcation of males by sunlight
exposure, as this may provide useful insights into themechanism of
action of alfacalcidol in early type 1 diabetes.
4.4. Conclusions
The study conﬁrmed that supplementationwith alfacalcidol can
safely preserve islet beta cell function in newly diagnosed type 1
diabetes in children and adolescents, with the effect being stronger
in males than females. However, the effects are modest at the
dosage used, and long-term outcomes are still unknown.
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